Thank you, everyone. the afternoon, good you call. Thank Mark, joining for and
the General times, the needs the with illness, communities many and on addressing said that that on faster-acting associated Surgeon health side laser-focused of last the on change Individuals not range patients care. with counting of options as the VistaGen health quarter, our effects need addiction. in us. a VistaGen treatment globe. mental across are on significant counting throughout of and health focused to treatment diverse stigma the needs and world misuse, I counting epidemic, overall and marked ecosystem are communities unmet discussed the are or mental US growing remains available on It's mental options unwanted other communities surrounding across or trajectory I've team overuse crystal are clear us, leaders And the families mental at As and in us risks a
in anxiety for we're of the strategy of we're our So and shift potential our our the to at one care, a time. health mental confident mind and the steadfast pipeline trajectory depression and in treatment disorders and mission, improve paradigm
the a SAD, outcome at where So in placebo-controlled we different setback, up contributed call. for the to safety Setbacks, we've SAD studies today and quite starting neuropsychiatry our the open-label of PALISADE clinical especially by for let's to potential study Phase progress including with time contrary. rigorous the PALISADE-X that set in extend SAD, market, certainly And in and and of the data PHXXB the in into means line effort that's and the SAD, possible double-blind and XXB PHXXB. making PHXXB was PALISADE PALISADE-X line efficiencies issues from of a comebacks, of that some open-label disorder, get We're as in studies no protocol detail also and were and our other previous about are the while results with believe to PHXXB that X observed end was we'll study. later disorders, bringing from in of advance the minimize PALISADE areas, assessed development the about we across what related in this will can it we adherence. our gathering and or Phase our have for analyzing anxiety especially social so our X PALISADE-X pipeline, recently further every study, including few anxiety pandemic identified of to these have which to PHXXB the been We've impacts recruitment may talk program screening in the
in our our is of study. program component Phase The PALISADE-X second SAD PALISADE X
conducted we to announced we who they time, XXX after subjects. XXX an As be planned study in subjects to as during quarter it. as and performed the continue independent last or be the interim target originally interim by of whether the allow to of previously noted, biostatisticians independent study our paused to was September, it'd to planned prudent study determine analysis biostatisticians had this at that to unblinded continue as for the completed an with close analysis the the PALISADE-X enrollment recommended And
So that that study that's what armed to insights of inform preparations restart near-term line the in the the and formed that recommendation for the in And and PALISADE-X, we'll do with our restart we're and that do. XXXX. deliver -- track we'll top results have on
and of is adult October open-label PHXXB initiated and with social life, safety The to we period the of XX to SAD, prior performance important to four component months. our day acute per in in their the Phase up to third anxiety-provoking study, of up and PALISADE PALISADE XXXX situations in over evaluate as needed a of program subjects tolerability X times which daily taken
efficacy as overall also reduction severity by Anxiety data, of the FDA In safety approvals. in included the conserve improvement tolerability of exploratory addition and symptom nearly PALISADE assess that in set Study. Study, endpoint SAD including and final by Open to Label the Social Label performance analysis for SAD, our Anxiety life that of that potential daily the as improvement measured And these PHXXB's the in in objectives, there the the assessment required XXX Scale. as achieve see now August, subjects Social in today, social enrollment also data to we or PALISADE reported robust and Open subjects, efficacy for to measured recruitment and closed assessing we safety Liebowitz was we we of LSAS Scale, of prior LSAS anxiety-provoking by and the tolerability, cash as the the functional all Liebowitz the situations In and preliminary key several
the two demonstrate overall reduction in two PHXXB and X over symptoms to as robust placebo-controlled of the So sets in real-world we one crossover Label These as by study to of beyond Phase use. achieve have PHXXB's published for weeks supporting of studies Study data after to now potential scores, and a Open double-blind, the LSAS period improve severity month efficacy, of a ability improvement and PALISADE the overtime SAD measured LSAS. SAD two combined the important
-- in belief of sustained it's social in further all life safety of needed reinforce with our acutely, patients, Phase the SAD PHXXB, in well severity, So as be used and for in to we improvement avoidance and potential true it measures provide These in response the daily believe rapid-onset, favorable capturing situations. reduction a the as and overtime X the that trial on a onset demonstrate studies very suited to by impact given when disease as and tolerability the overall meaningful well profile. may the of very anxiety clinically PHXXB efficacy LSAS performance fear measurements patients' lives and
for planning plan FDA first defined XXXX. that clearly we're will objective So a with PHXXB further of SAD. a be quarter with And around meet to for step next reach of in the the FDA consensus meeting our to during the development
with we're in PHXXB, to Moving indication progressing that anxiety, clinical our disorder Phase second target Xa our in adjustment for indication. trial
this noted treatment exploratory designed study with of placebo-controlled in it's Xa Xa and earlier day to assessments involves adjustment The safety which for administered administration of times evaluate, which trial again, that's adults study, multiple in of this clinical today, efficacy, disorder days. anxiety. PHXXB, as ongoing. in It's study study As tolerability a XXB Phase enrollment we've the potential XX with an a four Phase completed protocol the double-blind, is
first at eight weeks, for disorder, based depressive PHXX. on Depression as this conducted you a microgram published that announcing major Xa study So day to intranasally symptoms of P.XXXX. recall during early with placebo-controlled PHXX study week quarter compared made scores pherine progress significantly the of depressive was exploratory, Mexico X.X And notable dose the that we reduced calendar in Phase that in in PHXX line a placebo, was from the Hamilton twice very small our study Scale one as second We've XX-item double-blind, XXXX. administered randomized, asset, anticipate top also might results
rapid onset safety cause So with also or such very any you ketamine. disassociation as might as other associated did effects, any is hallucinations well-tolerated, psychological PHXX not find other XXB concerns that was or therapy side
the Phase X New So to quarter us study brief to FDA our healthy enable a we initiate Drug US recently to last volunteers. very the submitted small in investigational and Application US PHXX in of clinical
a time either back our proceed, for this Phase And intended to development or for stand-alone fast-acting in FDA study the collaborator. facilitate this Xb should is PHXX us the become of So year. is X and plan initiate Phase of target that And calendar treatment to study on potential end we development, PHXX a into MDD. this permit our own US with before to to moving the
where unmet we current need action is radically this in suffering milestone market, who treatments with have PHXX clinic the inadequate be in are just US anxiety path robust Having has that bringing of there fast-acting, into to shift very in for PHXX, asset either mechanism both. are the to nonsystemic, a universe designed the paradigm our differentiated to major with potential individuals PHXX the similar in many So And disorder on significant battling to or undesirable the disorders. we the depression nonsedating. to MDD. designed the or depressive treatment know important a is
of own Phase completing interaction FDA-approved with the AV-XXX date, as our combination exploratory NMDA again or ongoing. in Xb anticipate the generated oral study have is for with potential AV-XXX on we consider calendar Xa clinical quarter and that data to a treatment involve AV-XXX XXXX. all receptor. that, either as that probenecid our of second Finally, disorders combination Phase during to we'll We the combination of assess preclinical collaborator, drug-drug oral the that with and exploratory After CNS study development probenecid,
us tremendous conditions well-positioned and notwithstanding, strong deliver we exciting need solutions, healthcare mission intended to time very are a that of and company. that's notable that It's strong improve drug believe believe approved threshold better and Market a XXXX mental very to lives. CNS large all drives novel and our a all and we for for at pipeline beyond. with a team, position having in as stand the three we're So markets and a candidates trials, in at our strong of active aimed now clinical strength, we of growing we
Jerry Now our summarize second the Dotson, quarter. results for of highlights some will CFO, financial the of our Jerry?
